Emergent BioSolutions wins $24 million BARDA contract modification for CYFENDUS anthrax vaccine supply - EBS News | RalliesEmergent BioSolutions wins $24 million BARDA contract modification for CYFENDUS anthrax vaccine supply
E
EBS• BARDA contract modification for CYFENDUS supply
- Emergent BioSolutions received a contract modification valued at about $24 million from BARDA to supply CYFENDUS for U.S. anthrax preparedness.
- CYFENDUS is an FDA-cleared two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65 when used with antibacterial drugs.
- The award extends the company’s U.S. government anthrax vaccine supply work, following a delivery order valued at up to $21.5 million for BioThrax.
•
